Bortezomib Provides No Benefit Over R-DHAP Alone in R/R DBLCL
Overall, there was no improvement in complete response or survival outcomes among patients who received bortezomib.
Overall, there was no improvement in complete response or survival outcomes among patients who received bortezomib.
A large proportion of patients with relapsed/refractory diffuse large B-cell lymphoma do not undergo repeat biopsy, a study suggests.
A model including 4 clinical factors can predict overall survival, with predictive performance superior to the Ann Arbor staging system.
Researchers sought to develop a model to classify patients with diffuse large B-cell lymphoma into prognostic subgroups.
This phase 3 trial is designed to compare loncastuximab tesirine plus rituximab with standard immunochemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma.
Patients who received Pola-R-CHP were less likely to need subsequent treatment compared with those who received standard R-CHOP.
The median duration of response was not reached in patients with follicular lymphoma or diffuse large B-cell lymphoma.
Researchers sought to determine whether tafasitamab with lenalidomide would improve outcomes for patients with relapsed/refractory DLBCL.
Survival outcomes were comparable for patients who received tisagenlecleucel and those who received lisocabtagene maraleucel.
Response and survival outcomes were similar with rituximab biosimilars and the originator.